Viatris Inc.
$19.11
+0.34 · +1.78% today
Market open · updated 12:45:29 PM ET
- High
- $19.14 9:55 AM
- Low
- $18.77 7:40 AM
Against the S&P 500 Price change through Oct 28, 2026
VTRS+50.76%
S&P 500+13.26%
VTRS+82.41%
S&P 500+12.41%
VTRS+114.03%
S&P 500+88.06%
VTRS+40.81%
S&P 500+68.51%
Key numbers
- Previous close
- $18.77
- Open
- $18.97
- Day's range
- $18.93 – $19.17
- 52-week range
- $9.92 – $19.17
- Volume
- 6.0 million
- Average volume
- 9.3 million
- Market value
- $21.9 billion
- Earnings per share
- -$0.35last 12 months
- Beta
- 0.86moves about as much as the market
- Dividend
- $0.48 a year · 2.56%
- 50-day average
- $17.34
- 200-day average
- $15.84
Thursday, Nov 5, 2026, before the open.
Analyst price targets and the full financials are in the terminal.
Who Viatris sells to From our value chain
Viatris in the news
No desk stories on VTRS yet. When we write about it, the story leads this list.
- HeadlineViatris (VTRS) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research · October 29, 2026 at 11:01 AM ET
- HeadlineWill Viatris (VTRS) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research · October 27, 2026 at 1:11 PM ET
- HeadlineWhy Viatris (VTRS) is a Top Momentum Stock for the Long-TermZacks Investment Research · October 26, 2026 at 10:51 AM ET
- HeadlineHere's Why Viatris (VTRS) is a Strong Value StockZacks Investment Research · October 20, 2026 at 10:41 AM ET
- HeadlineViatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of PresbyopiaPRNewsWire · October 16, 2026 at 4:05 PM ET
- CongressJohn Fetterman sold $1,001 - $15,000 of VTRSSenate filing · disclosed May 15, 2025
- CongressRob Bresnahan sold $1,001 - $15,000 of VTRSHouse filing · disclosed May 8, 2025
- CongressGilbert Cisneros sold $1,001 - $15,000 of VTRSHouse filing · disclosed Apr 8, 2025
Earnings
Next report: Thursday, Nov 5, 2026, before the open.
Congress trades in VTRS
1 purchase and 3 sales in the latest 4 filings.
| Member | Trade | Amount | Traded | Disclosed |
|---|---|---|---|---|
| John FettermanSenate · D-Pennsylvania | Sale | $1,001 - $15,000 | Apr 22, 2025 | May 15, 2025 |
| Rob BresnahanHouse | Sale | $1,001 - $15,000 | Apr 8, 2025 | May 8, 2025 |
| Gilbert CisnerosHouse · D-California | Sale | $1,001 - $15,000 | Mar 31, 2025 | Apr 8, 2025 |
| Ro KhannaHouse · D-California | Purchase | $1,001 - $15,000 | Nov 15, 2024 | Dec 6, 2024 |
Source: Periodic transaction reports filed with the House and the Senate · Members disclose ranges, not exact amounts, and may file weeks after the trade.
About Viatris
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 30,000
- Headquarters
- Canonsburg, Pennsylvania
- Website
- viatris.com
- Listed
- Mar 17, 1980
More drug manufacturers - specialty & generic stocks
The price refreshes every 15 seconds while the market is open and carries the time it was read. Company figures are updated each evening. Built from WiseView and market data and public filings. For information only, not investment advice.